Brief: SAB Biotherapeutics Unveils New Data At Isirv Options XI Conference Validating SAB-176 Proof Of Concept In Reducing Viral Load And Improving Symptoms Of Influenza And Showing SAB-185 Effective Against Multiple Covid-19 Variants Including Omicron
28/09/2022 13:21
Sept 28 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS UNVEILS NEW DATA AT ISIRV OPTIONS XI
CONFERENCE VALIDATING SAB-176 PROOF OF CONCEPT IN REDUCING VIRAL
LOAD AND IMPROVING SYMPTOMS OF INFLUENZA AND SHOWING SAB-185
EFFECTIVE AGAINST MULTIPLE COVID-19 VARIANTS INCLUDING OMICRON
Source text for Eikon: ID:nGNX1mhq3q
Further company coverage: SABS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies